Power analyses suggest that a sample of >900 TOF subjects would be required to achieve Bonferroni-corrected p-value < 0.05 for ultra-rare truncating variants in KDR, and an even larger sample size of >1,600 TOF subjects would be required for FOXO1, WNT5A and ZFAND5. Identifying other, more homogenous subsets within the broader CHD spectrum may also be beneficial. This evidence concerns the gene WNT5A and coronary artery disorder.